Computational Design of a Multi-Epitope mRNA Vaccine Candidate Targeting Merkel Cell Polyomavirus
Background: Exploring a vaccine candidate that combines viral antigens
A multi-epitope mRNA vaccine candidate targeting four proteins of Merkel cell polyomavirus (MCPyV) was designed computationally. Published in Scientific Reports, the study used computational tools from antigen candidate selection to structure prediction and immune-response simulation. It did not demonstrate immunogenicity or cancer-treatment effects in humans or animals.
MCPyV infection is common and usually asymptomatic, but virus-associated Merkel cell carcinoma (MCC) is a research target for vaccine-based immunotherapy. The researchers sought epitopes—regions recognized by the immune system—in VP1 and VP2, which form the viral capsid, and in large T antigen and small T antigen, which are involved in tumor formation. This approach combines antigenic regions from multiple proteins to propose a candidate construct for evaluation in follow-up experiments.
Key findings: From antigen selection to predictions of structure and immune response
The researchers predicted epitopes recognized by cytotoxic and helper T cells, then selected candidates using computational assessments of antigenicity, allergenicity, toxicity, and water solubility. They linked the selected epitopes and included human beta-defensin-1 as an element intended to enhance the immune response. The mRNA design also included regulatory sequences chosen with translation and stability in mind. Predictions of non-toxicity and non-allergenicity do not substitute for safety testing involving actual administration.
After modeling the three-dimensional structure of the protein encoded by the construct, the team used molecular docking to explore its interaction with Toll-like receptor 3 (TLR3). Molecular dynamics analysis examined how the structure moved over 100 ns. The researchers interpreted the computational results as suggesting possible interaction with the receptor, but these results must be distinguished from measurements of actual binding or activation of TLR3 signaling.
In the immune-response simulation tool C-ImmSim, the team specified three administrations while maintaining the baseline immune environment. The simulation showed responses involving several immune cell types, including B and T cells. Because these are predictions under virtual conditions, they cannot be interpreted as demonstrating patient-specific dose adjustment or tumor suppression. Codon optimization assuming an Escherichia coli (E. coli) expression system yielded a reported codon adaptation index (CAI) of 1.0 and GC content of 53.41%. These are sequence-design metrics; they do not indicate actual expression levels or mRNA vaccine manufacturing performance.
Implications and outlook: Candidate design ahead of experimental validation
The study assembled a vaccine candidate by selecting antigenic regions from four viral proteins and presented computational results to inform follow-up validation. However, the abstract and full text contain discrepancies in the number of epitopes, hydrophilicity metrics, and binding free-energy values. These figures are difficult to present as conclusive evidence of performance, and no experimental comparison showing superiority over existing vaccines was reported.
The researchers explicitly state that safety, immunogenicity, and protective effects need to be assessed in cell and animal experiments. Further work must verify whether actual expression, antigen presentation, and immune responses occur as intended. The current results cannot establish prevention of infection, efficacy against MCC, feasibility of large-scale production, or a shorter approval timeline. The methods and results are available in the full paper.
The pathogenesis of Merkel cell polyomavirus (MCPyV) is characterized by ubiquitous and most likely silent childhood infection that may cause Merkel cell carcinoma (MCC). This mRNA vaccine includes the capsid proteins VP1 and VP2, as well as the Large T antigen and small T antigen, which are highly immunogenic. This has led to the development of mRNA vaccines against these T and Capsid peptides. Different computational methods was used to identify the epitopes of helper CD4 + lymphocytes and CD8 + lymphocytes. All of selected epitopes was analyzed for their toxicity, allergenicity, and immunogenicity. The MD simulation was carried out in an orthorhombic TIP3P water box with a buffer region of 10 Å, and Na+/Cl- counter ions at a physiological amount of salt (150 mM) were added to neutralize the system. Once the NVT and NPT aggregates were equilibrated, a 100 ns manufacturing run at 310 K and 1 atm was performed. Our vaccine has 19 epitopes in the vaccine construct, including HTLs and CTLs. The vaccine was found to have an increased hydrophilicity, and the average hydropathicity score was - 8.95. The Ramachandran plot revealed potential stability, 94.6% of the amino acid units were found in the allowed region. The vaccine showed potentially high affinity with the TLR3 receptor as the docking score was - 318.56 KJ/mol, and the confidence score was 0.9668. After codon optimization, there was a knowing improvement in the expression in E. coli vectors that produced vaccines, as indicated by the increase in GC content to 53.41. MM-GBSA analysis showed that there was a uniform binding affinity of TLR3 between - 1500 and - 2000 kcal/mol. Our vaccine construct against MCPyV showed potential immune responses and should be advanced to in vitro and in vivo clinical experiments.
This study proposes an antigen combination and construct design that teams researching MCPyV-related vaccines can evaluate in follow-up experiments. For example, it could serve as a starting point for checking whether the candidate sequence is actually expressed, then assessing step by step whether its epitopes are presented to immune cells and elicit T-cell responses. The role of the computational results is to help select candidates for testing.
However, discrepancies in the source material concerning epitope composition and numerical values should first be checked, and actual expression, safety, and immunogenicity must be validated. Codon optimization results for E. coli also need to be evaluated separately from mRNA manufacturing and delivery performance. Docking and immune-response simulations alone cannot establish patient benefit; further experimental evidence is needed to discuss potential clinical applicability.